Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.

• DOI: 10.1200/jco.1996.14.3.859
• Publication Date: 2017-02-24T09:47:02Z
• Authors: P W Pisters; L B Harrison; D H Leung; J M Woodruff; E S Casper; M F Brennan
• Keywords: Distant metastasis

PURPOSE This trial was performed to evaluate the impact of adjuvant brachytherapy on local and systemic recurrence rates in patients with soft tissue sarcoma. PATIENTS AND METHODS In a single-institution prospective randomized trial, 164 were intraoperatively receive either (BRT) or no further therapy (no BRT) after complete resection sarcomas extremity superficial trunk. The radiation administered by iridium-192 implant, which delivered 42 45 Gy over 4 6 days. two study groups had comparable distributions patient tumor factors, including age, sex, site, size, histologic type grade. RESULTS With median follow-up time 76 months, 5-year actuarial control 82% 69% BRT (P = .04), respectively. Patients high-grade lesions 89% 66% .0025). low-grade .49). freedom-from-distant-recurrence 83% 76% .60), Analysis grade did not demonstrate an development distant metastasis, despite improvement noted lesions. disease-specific survival for 84% 81% .65), respectively, regardless CONCLUSION Adjuvant improves sarcomas. is limited histopathology. reduction associated significant metastasis survival.